The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA

  • days left to enroll
  • participants needed
  • sponsor
    Qilu Hospital of Shandong University
Updated on 26 June 2021
autoimmune disease


RA is a common autoimmune disease that causes joint damage.It is necessary to reach the standard as soon as possible and give effective drugs according to the patient's disease activity to avoid disability. Tofacitinib(TF) is a new type of oral tyrosine kinase inhibitor (JAKi) for the treatment of moderate to severe active RA. However, there is alack of Chinese data on the joint scheme, long-term use, maintenance and stop of TF in the real world. We will use the new JAK combination regimen to treat RA patients, and carry out long-term clinical follow-up for 30 weeks.


Objective: To observe the clinical efficacy and safety of TF combined with/ without IGU for 30 weeks in patients with moderate to severe active RA with different clinical characteristics and subgroups by using a prospective cohort , and to find the best combination scheme of TF.

Condition Rheumatoid Arthritis (Pediatric), Rheumatoid Arthritis
Treatment tofacitinib, Iguratimod, Pred
Clinical Study IdentifierNCT04928066
SponsorQilu Hospital of Shandong University
Last Modified on26 June 2021


Yes No Not Sure

Inclusion Criteria

Patients who meet the following inclusion criteria will be eligible to
participate in the
Patients who meet RA standards in 1987 and 2010 or ERA standards in 2012
Age > 18 years old
the extrapulmonary manifestations of RA were stable
Patients with NSAIDs tolerance
DAS28-ESR is highergreater than 2.6

Exclusion Criteria

Patients who meet any of the following criteria will be excluded from the
Patients with acute and chronic infection
Platelet count < 80 _10^9/L, or white blood cell < 3_10^9/L
ALT or AST is 2 times higher than the upper limit of normal value
Renal insufficiency: serum Cr 176 umol/L
Pregnant or lactating women (breastfeeding)
Have a history of malignant tumor (the cure time is less than 5 years)
Patients with severe hypertension and cardiac insufficiency
Other diseases or conditions in which immune suppressants cannot be used
People who are allergic to TF
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note